ArticleImmunoTargets and therapy2025

Anti-CD24 Antibody Plus Liposomal Doxorubicin for the Management of Residual Cancers After Incomplete Radiofrequency Ablation.

Jiayun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.